A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors.

Trial Profile

A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 09 May 2013

At a glance

  • Drugs Vadimezan (Primary) ; Carboplatin; Cetuximab; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Feb 2011 Actual initiation date changed from Dec 2009 to Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top